8-K filing — GLAUKOS Corp (GKOS)
Filed: 2026-11-06 AccNo: 0001193125-26-450710 Size: 16 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Filings · News reference
Glaukos Insider Executes Significant Share Sale
A Glaukos Corporation insider has sold shares valued at approximately $10.6 million, as disclosed in a recent SEC filing.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BDX Gears Up to Report Q4 Results: How to Play the Stock?
Becton Dickinson (BDX) is set to report Q4 fiscal 2026 results on Nov. 5, with EPS expected to grow 2.53% despite a 13% revenue decline. While Medical Essentials and Interventional segments show strength, China market challenges and a 200-basis-point Alaris revenue headwind are expected to weigh on quarterly performance. The company has a positive Earnings ESP of +0.21% and Zacks Rank #2, suggesting an earnings beat is unlikely despite historical performance.
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Corporation management is scheduled to participate in the Stifel Healthcare Conference and the Jefferies Global Healthcare Conference in November 2026.
Wall Street Analysts Adjust Price Targets for Glaukos Following Q3 Earnings
Multiple financial institutions, including Citigroup, Truist, and Needham, raised their price targets for Glaukos Corporation following the company's strong third-quarter earnings report.
Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday
Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
Wells Fargo Maintains Overweight on Glaukos, Raises Price Target to $226